Septic Shock Clinical Trial
— HyperBetashockOfficial title:
Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility: an Open Label Prospective Randomized Study
Several data emphasize the relation between tachycardia (>90/min) and high mortality during septic shock. The investigators previously demonstrated the high mortality associated with hypercontractility, tachycardia and the presence of a left ventricular obstruction. A severe hypovolemia, a hyper adrenergic stimulation or a severe vasoplegia can all explain this relation between tachycardia, hypercontractility and the mortality during septic shock. Landiolol is another short-term acting beta-blocker with a half-life of 4 minutes without any beta 2 activity or membrane stabilizing effect. The landiolol has been used in critically ill patients to control supraventricular tachycardia but not in this context of tachycardia and septic shock. The investigators hypothesize that landiolol by reducing the heart rate may improve the survival of patients treated for a septic shock and presenting with an hypercontractility state.
Status | Recruiting |
Enrollment | 360 |
Est. completion date | March 2024 |
Est. primary completion date | February 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years old - Patient admitted for a septic shock (according to the SEPSIS3 definition: sepsis with persisting hypotension (MAP<65mmHg or SAP <90mmHg) requiring vasopressors to maintain MAP>65mmHg and having a serum lactate level >2 mmol/L - Patient who received at least 30ml/kg of fluid and absence of fluid responsiveness - Left ventricular ejection fraction >65% (visual or Simpson method using echocardiography) - Tachycardia >100 bpm in sinus rhythm with a MAP 65mmHg for more than 1 hour - Patient receiving invasive mechanical ventilation - Patients adapted to the ventilator under sedation and analgesia - Written informed consent - Patient covered by French national health insurance Exclusion Criteria: - Patients with inclusion criteria already present for more than 36 hours - Patient treated with Dobutamine, adrenaline or isoprenaline - Patient currently treated with beta blockers (previous home betablocker treatment is not an exclusion criteria) - Supra ventricular (atrial fibrillation or flutter) or ventricular arrhythmias - Patients with any form of cardiac pacing - Sick sinus syndrome - Severe atrioventricular (AV) nodal conductance disorders (without pacemaker): 2nd or 3rd degree AV block - Known pulmonary hypertension - ScVO2 <70% - Moribund - Cardiac arrest - Non-treated phaeochromocytoma - Acute asthmatic attack - Pregnant or breastfeeding woman - Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision), - Age <18 years - Hypersensitivity to the active substance or to any of the excipients - Severe bradycardia (less than 50 beats per minute) - Cardiogenic shock - Severe hypotension - Decompensated heart failure when considered not related to the arrhythmia - Severe, uncorrectable metabolic acidosis - Presence of significant bleeding, or - Acute respiratory distress defined by increased oxygen dependency, polypnea > 30 /min, signs of struggle (pulling, thoraco-abdominal sway) if the patient is not intubated and ventilated. |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens | Amiens |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire, Amiens | Centre Hospitalier Arras, Centre Hospitalier de Beauvais, Centre Hospitalier de Bethune, Centre Hospitalier de Lens, Centre Hospitalier de Roubaix, Centre Hospitalier Universitaire de Nimes, Centre Hospitalier VALENCIENNES, CH Calais, CH Cherbourg, CH Compiègne, CH Dieppe, CH Douai, CH Elbeuf, CH Laon, CH Le Havre, CH Lomme, CH Montreuil, Groupe Hospitalier Pitié-Salpêtrière, Henri Mondor University Hospital, Hôpital Edouard Herriot, Hospital Ambroise Paré Paris, Hospital Avicenne, Tourcoing Hospital, University Hospital, Brest, University Hospital, Caen, University Hospital, Lille, University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Variation of mortality rate in landiolol group compared to control group | day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 | |
Completed |
NCT02204852 -
Co-administration of Iloprost and Eptifibatide in Septic Shock Patients
|
Phase 2 |